A California legislator has launched an effort to terminate the $3 billion California stem cell agency, which is already set to go out of business in about three years.
Republican state Sen. John Moorlach of Costa Mesa said in a video, “It’s time to shut this down….We as taxpayers need some protection. We need to stop the boondoggle.”
Moorlach has authored a proposed constitutional amendment that has been referred to the Senate Health Committee. No hearing date has been set. The measure would strip from the state constitution the language that created the agency in 2004.
The proposal, SCA7, requires a two-thirds vote of both houses of the Legislature and approval by a vote of the people. Given the Democratic dominance of the Legislature, that makes the chances of enactment of SCA7 unlikely.
Nonetheless, Moorlach’s effort reflects the sentiments of a certain segment of the public. It also provides ammunition for those seeking to fund the agency with another $5 billion, which would additionally be placed before voters, probably in November 2018. It is useful for campaigns for such measures to be able to point to what they consider threats to science and medical progress.
Backers of a $5 billion bond measure are proposing it because the agency is slated to run out of cash for new research awards by June 2020.
Moorlach’s office produced a short statement in support of elimination of the California Institute for Regenerative Medicine or CIRM as the agency is formally known. It said, “California voters approved a ten year stem cell program that they thought would produce widespread cures and save thousands of lives. They were also promised revenue-producing intellectual property that would help the state financially. These remain empty promises.
“More than thirteen years after its passage, around $2 billion in funds have been dispersed and $1.2 billion has been spent on servicing the principal and interest of the debt . With a $1.6 billion dollar budget deficit and crumbling infrastructure, we need to stop the issuance of bonds on an ineffective and unaccountable agency. Scarce taxpayer funds could be of better use elsewhere.”
Asked for a comment on the legislation, an agency spokesman, Kevin McCormack, said, “We are aware of the bill and are monitoring it.”
Ed’s Note: David Jensen is a retired newsman who has followed the affairs of the $3 billion California stem cell agency since 2005 via his blog, the California Stem Cell Report, where this story first appeared. He has published more than 4,000 items on California stem cell matters in the past 11 years.